| 主权项 |
1. A method for treating a FLT3 mutated cancer in a subject, wherein the FLT3 mutated cancer carries a D835Y, Y842C, K663Q or V592A mutation, the method comprising:
a) determining if the subject's cancer carries a D835Y, Y842C, K663Q or V592A mutation; and b) if the cancer is determined to carry a D835Y, Y842C, K663Q or V592A mutation, administering to the subject a composition comprising at least one compound of formula (I): wherein:
R1 is HR2 is a moiety selected from the group consisting of H and trifluoromethylcarbonyl; or R1 and R2 are taken together with the core structure to form a heterocyclydiyl moiety of formula (a): R3 is a moiety selected from the group consisting of —ORa and —NRbRc;Ra is a C1-4 alkyl group optionally substituted with an imidazolyl;Rb is a moiety selected from the group consisting of a C1-4 alkyl group and a C1-4 alkoxy group, wherein Rb is substituted with 0, 1 or 2 groups each independently selected from the group consisting of —OCH3, —C(O)OH, —C(O)NR′R″, —NH(C1-3 alkyl), —NH(CH2CH2O)nCH3, wherein n is 2-4, piperazinyl, N-methylpiperazinyl, piperidinyl, N-methylpiperidinyl, N-morpholinyl, imidazolyl, pyrrolidinyl, —OPO3H2 and hydroxyl; wherein the —NH(C1-3 alkyl) group is substituted with 0, 1 or 2 hydroxyl moieties and wherein R′ and R″ are each independently selected from —H or —CH3; andRc is H, or Rb and Rv are taken together with the nitrogen to which they are attached to form a heterocyclyl moiety selected from the group consisting of formula (b) and formula (c): or a pharmaceutically acceptable salt or ester thereof; in an amount effective for treating the FLT3 mutated cancer. |
